S100B is downregulated in the nuclear proteome of schizophrenia corpus callosum

Author(s)

Steiner, Johann ^{[1, 2]} ; Schmitt, Andrea ^{[3, 4]} ; Schroeter, Matthias L. ^{[5, 6]} ; Bogerts, Bernhard ^{[1, 2]} ; Falkai, Peter ^[4] ; Turck, Christoph W. ^[7] ; Martins-de-Souza, Daniel ^{[3, 7, 4]}

Affiliation

^[1] Univ Magdeburg, Dept Psychiat, D-39106 Magdeburg - Germany

^[2] Ctr Behav Brain Sci, Magdeburg - Germany

^[3] Univ Sao Paulo, Inst Psychiat, Lab Neurosci LIM 27, Sao Paulo - Brazil

^[4] Ludwig Maximilians Univ Munich LMU, Dept Psychiat & Psychotherapy, Munich - Germany

^[5] Max Planck Inst Cognit & Human Brain Sci, Leipzig - Germany

^[6] Univ Hosp, Clin Cognit Neurol, Leipzig - Germany

^[7] Max Planck Inst Psychiat, D-80804 Munich - Germany

• Document type: Journal article
• Source: EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE; v. 264, n. 4, p. 311-316, JUN 2014.
• Web of Science Citations: 10

Abstract

Here we report the downregulation of S100B in the nuclear proteome of the corpus callosum from nine schizophrenia patients compared to seven mentally healthy controls. Our data have been obtained primarily by mass spectrometry and later confirmed by Western blot. This is an intriguing finding coming from a brain region which is essentially composed by white matter, considering the potential role of S100B in the control of oligodendrocyte maturation. This data reinforce the importance of oligodendrocytes in schizophrenia, shedding more light to its pathobiology. (AU)

• FAPESP's process: 13/08711-3 - Developing a predictive test for a successful medication response and understanding the molecular bases of schizophrenia through proteomics
• Grantee: Daniel Martins-de-Souza
• Support Opportunities: Research Grants - Young Investigators Grants